Kozi Pharmaceuticals-B (02171) plans to repurchase up to approximately 25.46 million shares, and have major shareholders increase their holdings by 100,000 shares.

Zhixin Financial APP news, Koja Pharmaceutical-B (02171) announced that the previous share repurchase plan has now been updated by the board of directors to repurchase a maximum of 25,461,295 shares in the public market within 50 Hong Kong trading days starting from November 13, 2025. Under the updated share repurchase plan, a total of 25,461,295 shares, together with the shares repurchased in 2025, will account for 5% of the total number of shares issued on the day of the grant of the 2025 share repurchase authorization.